It began with a simple belief: precision RNA-targeted medicine could be made more effective and fundamentally safer. Over time, that belief shaped our science, became a platform, a growing pipeline, and a team working to bring these ideas into the clinic.
"We never accepted that side effects should be the unavoidable price of effective therapy. At Selecta, we are working to change that by developing oligonucleotides that are designed to be highly target-specific, with safety at their core. Ultimately, it is about giving patients better treatment options."
To improve patient healthcare through safer therapeutic solutions, delivering the desired therapeutic effect while helping patients maintain their quality of life.
Excellence-driven commitment to your health has guided every decision we have made for more than a decade.
From the first peer-reviewed studies to therapeutic leads advancing toward first-in-human trials.
More than a decade of research into unique oligonucleotide architecture, supported by peer-reviewed publications, laid the scientific foundation for everything that followed.
Extensive research into chronic myeloid leukemia, from predictive biomarkers to the identification and characterization of CML stem cells.
Framing the central challenge that would shape our work: achieving therapeutic activity with greater precision and fewer off-target effects.
Publication in Cancer Medicine marks a key step in our research. In the same year, Selecta Biotech SE is established in Bratislava as a European company (SE).
Our patented platform takes shape and earns European recognition, while certification and partnerships build the foundation for clinical translation.
An ESiNAR-X®-derived oligonucleotide demonstrated effective reduction of SARS-CoV-2 RNA levels, leading to the launch of the ASC1R therapeutic program.
Recognised at the Research & Development Awards, alongside Young Biotechnology Company of the Year at the Innovation & Excellence Awards.
Recognized at the Innovation & Excellence Awards and achieved ISO 9001 certification for quality management in research and development.
Therapeutic leads advance across oncology, infectious and renal diseases as Selecta expands its collaborations across Europe.
ASP210 shown effective against TKI-resistant CML cells; ASC1R demonstrates excellent tolerability and efficacy in vivo.
Presence at MEDICA 2025 in Düsseldorf and the OTS Annual Meeting – marking another step toward clinical impact.
Engaging Europe's biotech investment ecosystem at Swiss Biotech Day, as our lead programs approach the clinic.
Whether you are an investor, a research partner or a future colleague, we would be glad to write what comes next – together.
